Duan Zhongping, Dong Jinling, Liu Ying, Zhou Haiyang, Duan Shuli, Liu Weihong, Liang Rico, Ding Yue
Fourth Department of Hepatology Center, Beijing You'an Hospital, Capital Medical University, Beijing, People's Republic of China.
iGandan, the Portal for All Liver Disease Caring, Beijing, People's Republic of China.
Patient Prefer Adherence. 2023 Aug 22;17:2063-2072. doi: 10.2147/PPA.S422916. eCollection 2023.
HBV functional cure is an optimal treatment goal for chronic hepatitis B (CHB) at present and numerous new drugs aiming for HBV functional cure are in development. We carried out an internet-based survey to understand the treatment status, unmet needs, awareness of HBV functional cure and attitude toward related clinical trials among CHB patients in China.
An internet-based anonymous survey was conducted on CHB patients who reside in mainland China. Determinants of awareness and attitude were identified by logistic regression models.
Of the 1220 CHB patients who completed the survey questionnaire, 11.1% (135/1220) were aware of HBV functional cure and 50.2% (612/1220) answered "definitely will" to participate in related clinical trials. Participants who knew their HBsAg level (HBsAg<1500 IU/mL: OR=3.03, 95% CI: 1.87-4.92; HBsAg≥1500 IU/mL: OR=2.57, 95% CI: 1.35-4.88), who expected to achieve HBsAg loss with treatment (OR=1.63, 95% CI: 1.07-2.50) and who were dissatisfied with current treatment due to the failure of achieving HBsAg loss (OR=1.67, 95% CI: 1.10-2.53) had better awareness of HBV functional cure. Participants who had HBsAg level less than 1500 IU/mL (OR=1.45, 95% CI: 1.05-1.99), treatment with pegylated interferon alpha with or without nucleos(t)ide (OR=1.68, 95% CI: 1.11-2.53) and better awareness of HBV functional cure (OR=1.62, 95% CI: 1.01-2.61) were more likely to say "definitely will" to participate in related clinical trials.
Chinese CHB patients reported a low awareness of HBV functional cure. Although CHB patients in China reported a low rate of HBV functional cure awareness, they had a high acceptance of related clinical trials.
乙肝功能性治愈是目前慢性乙型肝炎（CHB）的最佳治疗目标，众多旨在实现乙肝功能性治愈的新药正在研发中。我们开展了一项基于网络的调查，以了解中国CHB患者的治疗现状、未满足的需求、对乙肝功能性治愈的认知以及对相关临床试验的态度。
对居住在中国大陆的CHB患者进行了一项基于网络的匿名调查。通过逻辑回归模型确定认知和态度的决定因素。
在1220名完成调查问卷的CHB患者中，11.1%（135/1220）知晓乙肝功能性治愈，50.2%（612/1220）回答“肯定会”参加相关临床试验。知晓自身乙肝表面抗原（HBsAg）水平的参与者（HBsAg<1500 IU/mL：比值比[OR]=3.03，95%置信区间[CI]：1.87 - 4.92；HBsAg≥1500 IU/mL：OR=2.57，95% CI：1.35 - 4.88）、期望通过治疗实现HBsAg转阴的参与者（OR=1.63，95% CI：1.07 - 2.50）以及因未实现HBsAg转阴而对当前治疗不满意的参与者（OR=1.67，95% CI：1.10 - 2.53）对乙肝功能性治愈的认知更好。HBsAg水平低于1500 IU/mL的参与者（OR=1.45，95% CI：1.05 - 1.99）、接受聚乙二醇化干扰素α联合或不联合核苷（酸）治疗的参与者（OR=1.68，95% CI：1.11 - 2.53）以及对乙肝功能性治愈认知更好的参与者（OR=1.62，95% CI：1.01 - 2.61）更有可能回答“肯定会”参加相关临床试验。
中国CHB患者对乙肝功能性治愈的认知较低。尽管中国CHB患者对乙肝功能性治愈的知晓率较低，但他们对相关临床试验的接受度较高。
